Luton, Bedfordshire, United Kingdom, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed and published the final copy of the detailed research report on the Benign Positional Vertigo Treatment Market.
The Global Benign Positional Vertigo Treatment Market is expected to reach USD 1,760 Million at a CAGR of 4.2% during the forecast period 2022 2029.
Benign Positional Vertigo Treatment Market (BPPV) is a type of vertigo that makes you feel like you are spinning. Shortly after beginning, this sensation ends on its own. The labyrinth system, which controls the body's balance and is housed inside the inner ear, is linked to benign positional vertigo. The free-floating particles in the inner ear can occasionally exert enough force to cause benign positional vertigo symptoms. Other causes of benign positional vertigo symptoms include viral infection, nerve irritation, challenges following ear surgery, medicine side effects, and unexpected head movement. Vomiting, sweating, unusual eye movements, and nausea are typical signs of benign positional vertigo. Additional symptoms include difficulty walking, speaking, hearing loss, and visual distortion.
The Epley technique and Brandt-Daroff are easy exercises that can be used to treat benign positional vertigo. When treating benign positional vertigo, the Dix-Hallpike test and the Roll test are used to determine whether the posterior semicircular canal and horizontal semicircular canal are both involved. Procedures and medications are both possibilities for treating benign positional vertigo. Benign Positional Vertigo Treatment Market is treated with anti-histamine, anti-cholinergic, anti-depressant, or sedative-hypnotic medicines.
Get the Sample Copy of Benign Positional Vertigo Treatment Market Strategic Report:
North America Captures the Largest Market Share Of Benign Positional Vertigo Treatment Market
Geographically, the world market for therapies for Benign Positional Vertigo Treatment Market is divided into North America, Europe, Asia-Pacific (with Japan excluded), the Middle East and Africa, and Japan. It is anticipated that North America and Europe would see strong revenue growth as a result of increased knowledge of the advantages of treating Benign Positional Vertigo Treatment Market as part of routine examinations.
Additionally, the procedure's lower cost as compared to other alternative therapies and low risk of consequences have led to an increase in the market for Benign Positional Vertigo Treatment Market in the regions.
Recent Development of Benign Positional Vertigo Treatment Market: -
- Astellas Pharma Inc and Pfizer Inc. announced results from the Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC). The results show that the use of XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71 percent compared to ADT alone.
| Report Attribute | Details |
| The revenue forecast in 2029 | 1,760 Million |
| Growth Rate | CAGR of 4.2% from 2022 to 2029 |
| The base year for estimation | 2021 |
| Historical data | 2017-2021 |
| Forecast period | 2022 - 2029 |
| Quantitative units | Revenue in USD billion and CAGR from 2022 to 2029 |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered | By Drug Class Type, By Distribution Channel, By Age Group |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; Japan; India; South Korea; Brazil |
| Key companies profiled | AstraZeneca plc., Intas Pharmaceutical Ltd., Cadila Pharmaceuticals, Pfizer Inc., Sanofi S.A., Medichem S.A., Liaoyuan Silver Eagle Pharmaceutical Co., Ltd., LGM Pharma, Marclabs, Sun Pharmaceutical Industries Ltd. |
Benign Positional Vertigo Treatment Market - Competitive Landscape
Due to the presence of prominent oncology market rivals and their broad product selection of oncology pharmaceuticals, the competitive landscape in the Benign Positional Vertigo Treatment Market exhibits rather intense competition. Numerous significant industry players include AstraZeneca plc., Intas Pharmaceutical Ltd., Cadila Pharmaceuticals, Pfizer Inc., Sanofi S.A., Medichem S.A., Liaoyuan Silver Eagle Pharmaceutical Co., Ltd., LGM Pharma, Marclabs, Sun Pharmaceutical Industries Ltd.
Technological Advancement Of Benign Positional Vertigo Treatment Market
In order to help doctors and other healthcare professionals precisely identify and effectively treat vestibular disorders, such as the most prevalent kind, known as BPPV, market participants are focused on technology innovation and broad accessibility of their unique product. The new technology gives caregivers the capacity to identify, classify, treat, and manage dizziness and balance issues in addition to providing an accurate nystagmus-based evaluation.
Browse In-depth Benign Positional Vertigo Treatment Market Report: -
Key Segments Of Benign Positional Vertigo Treatment Market
By Drug Class Type, it is segmented into
- Anti-histamine
- Anti-cholinergic
- Anti-depressant
By Distribution Channel, it is segmented into
- Hospital Pharmacy
- Retail Pharmacies
- Drug Stores
- Online Pharmacy
By Age Group, it is segmented into
- Pediatrics
- Adults
- Geriatrics
Browse More For Healthcare Market Reports
Multiple Sclerosis Therapies Market
Multiple sclerosis (MS) is a chronic, inflammatory, immune-mediated disease that can cause demyelination, axonal transection, and neurodegeneration of the spinal cord and brain's nerve cells. Some of the therapies that are widely used include the administration of drugs, physical therapy, muscle relaxants, and antidepressants. Dimethyl fumarate, Teriflunomide, and Cladribine are examples of oral treatments. Ocrelizumab, Natalizumab, and Alemtuzumab are intravenous infusion therapies. Interferon-beta and Glatiramer acetate are examples of injectable medications.
https://pharmaresearchconsulting.com/reports/multiple-sclerosis-therapies-market
Disruptive Behavior Disorder (DBD) Treatment Market
Children and adolescents with disruptive behaviour disorders (DBD) exhibit aggressive and defiant behaviours toward others. Oppositional defiant disorder (ODD) and conduct disorder (CD) are the two most common types of disruptive behaviour disorders (ODD). The main elements that are anticipated to drive the growth of the disruptive behaviour disorder treatment market in the forecast period include the increasing prevalence of substance abuse, the increasing incidence of mental disorders in children and teenagers, and the increasing initiatives taken by various NGOs and the government to increase understanding of the treatment of disruptive behaviour disorder.
https://pharmaresearchconsulting.com/reports/disruptive-behavior-disorder-dbd-treatment-market
Cervical Spondylosis Treatment Market
The ageing population and the rising incidence of spinal diseases are predicted to drive market expansion. The rise in spinal deformity cases can be attributed to a sedentary lifestyle. The market is also expected to grow as a result of the rise in cervical spondylosis incidence. Market growth is predicted to be fueled by the rising demand for minimally invasive procedures and state-of-the-art spinal implants. Minimally invasive spine (MIS) surgery enables quicker healing times, decreased postoperative discomfort, a decreased chance of muscle injury, a low risk of surgical site infection or complication, and other advantages.
https://pharmaresearchconsulting.com/reports/cervical-spondylosis-treatment-market
